Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
IPO Year:
Exchange: NYSE
Website: zimmerbiomet.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2026 | Mkt Perform | William Blair | |
| 1/9/2026 | $93.00 | Neutral → Sell | Goldman |
| 1/6/2026 | Outperform → Mkt Perform | Raymond James | |
| 1/5/2026 | $210.00 | In-line → Outperform | Evercore ISI |
| 12/16/2025 | $100.00 | Outperform → Neutral | Robert W. Baird |
| 11/6/2025 | $100.00 | Overweight → Neutral | Analyst |
| 9/18/2025 | $130.00 | Buy | Rothschild & Co Redburn |
| 7/15/2025 | $135.00 | Neutral → Buy | Roth Capital |
| 12/17/2024 | $125.00 → $128.00 | Neutral → Overweight | Analyst |
| 9/10/2024 | Peer Perform | Wolfe Research |
Fastest customizable press release news feed in the world
Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest SpeakerWARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker. On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzen
WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles
Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer
WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be webcast on Tuesday, February 10, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to d
WARSAW, Ind., Dec. 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer BiometZimmer Biomet is a global medic
WARSAW, Ind., Dec. 17, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2025. The cash dividend of $0.24 per share is payable on or about January 30, 2026 to stockholders of record as of the close of business on December 30, 2025. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We
OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility® Care Management Platform to Further Enhance Recovery Monitoring WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive collaboration agreement aimed at delivering the orthopedic industry's most comprehensive set of mobility data to further empower surgeons to track recovery progress more effectively following joint replacement surgery and enable patients to play an active role in their recovery.
ROSA® Knee with OptimiZe™ Offers Personalized Surgical Planning and Drives Confidence in Delivering Accurate and Reproducible Outcomes1 WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA® Knee System that offers a more customized experience for surgeons to help deliver accurate and reproducible outcomes1 in robotic-assisted total knee replacement surgery. ROSA Knee
WARSAW, Ind., Nov. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025, at Noon GMT (7 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer BiometZimmer Biomet is a global medical
Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basisThird quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidanceWARSAW, Ind., Nov. 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025. The Company reported third quarter net sales of $
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform
Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00
Raymond James downgraded Zimmer Biomet from Outperform to Mkt Perform
Evercore ISI upgraded Zimmer Biomet from In-line to Outperform and set a new price target of $210.00
Robert W. Baird downgraded Zimmer Biomet from Outperform to Neutral and set a new price target of $100.00
Analyst downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $100.00
Rothschild & Co Redburn initiated coverage of Zimmer Biomet with a rating of Buy and set a new price target of $130.00
Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00
Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously
Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform
SCHEDULE 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Live Leadership Updates
Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t
WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e
WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac
WARSAW, Ind., Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. Noor will be responsible for leading strategy development and execution and all facets of M&A, including the integration for our pending acquisition of Paragon 28. In addition, he will have oversight of the research and
WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including: Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025, pursuant to the mandatory director retirement age in the Company's Corporate Governance Guidelines;President and CEO Ivan Tornos will become Chairman of the Board upon Mr. Begley's retirement; andMichael Farrell
Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster over
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
WARSAW, Ind., Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President and Chief Executive Officer of the Hospital for Special Surgery (HSS), has been appointed to the Board, effective immediately. HSS has been recognized as a leading academic medical center focused on musculoskeletal health – it was ranked #1 in U.S. orthopedics hospitals for 14 years in a row by U.S. News & World Report and #1 in worldwide orthopedics hospitals by Newsweek for the past four consecutive years. Founded in 1863, HSS is the oldest orthopedics hospital in the U.S., performs more than 40,000 su
Chief Operating Officer Ivan Tornos Appointed President and CEO; Elected to the Board of Directors Chief Financial Officer Suketu (Suky) Upadhyay's Role Expands to CFO and EVP, Finance, Operations & Supply Chain Company Reaffirms Full-Year 2023 Financial Guidance WARSAW, Ind., Aug. 22, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served
Expanded Role Adds Responsibility for Environmental, Social and Governance (ESG) Strategy and Office of the CEO to Portfolio WARSAW, Ind., May 26, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE:ZBH) (SIX: ZBH), a global medical technology leader, today announced the appointment of Keri P. Mattox as Chief Communications and Administration Officer, reporting to President, Chief Executive Officer and Chairman Bryan Hanson. Ms. Mattox previously served as Senior Vice President, Investor Relations and Chief Communications Officer, and now adds responsibility for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CE
Live finance-specific insights
WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles
Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer
WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be webcast on Tuesday, February 10, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to d
WARSAW, Ind., Dec. 17, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2025. The cash dividend of $0.24 per share is payable on or about January 30, 2026 to stockholders of record as of the close of business on December 30, 2025. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We
Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basisThird quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidanceWARSAW, Ind., Nov. 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025. The Company reported third quarter net sales of $
Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures WARSAW, Ind., Oct. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the acquisition of Monogram Technologies Inc. ("Monogram"), an AI-driven, next-generation orthopedic robotics company. Monogram's surgeon-guided semi- and fully autonomous robotic technologies a
WARSAW, Ind., Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s
WARSAW, Ind., Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025. The cash dividend of $0.24 per share is payable on or about October 31, 2025 to stockholders of record as of the close of business on September 30, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025. T
WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so
This live feed shows all institutional transactions in real time.
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)